DNLI

NASDAQ · Biotechnology

Denali Therapeutics Inc

Mid-Cap Stocks Biotech Stocks Healthcare Stocks

$20.97

-0.12 (-0.57%)

As of Mar 24, 9:59 PM ET ·

Analyst Consensus

Strong Buy

Analysts

High

Coverage

Buy 23 92%

Hold 2 8%

Sell 0 0%

Price Target

Analyst Price Target +265.0% upside

Low Target $56.04

Average Target $76.55

High Target $105.76

Current Price $20.97

Current
$20.97

Target
$76.55

$56.04 $76.55 avg $105.76

Scenario Analysis

Bear Case

$56.04

167.2%

Low target

Base Case

$76.55

+265.0%

Avg target

Bull Case

$105.76

+404.3%

High target

Risk/Reward

2.4x

Favorable

Price in Context

52-Week High

$23.77

-11.8% from high

52-Week Low

$10.57

+98.4% from low

50-Day SMA

$18.67

+12.3% vs SMA

200-Day SMA

$15.96

+31.4% vs SMA

RSI (14)

42.3

Neutral

Target vs 52W High

$76.55

+222.0% vs high

Peer Consensus — Biotechnology

Stock	Consensus	Analysts	Buy %	Target	Upside
ABBV Abbvie Inc	Buy	39	69%	$257.58	+25.5%
AMGN Amgen Inc	Hold	42	50%	$190.87	-45.2%
GILD Gilead Sciences Inc	Strong Buy	37	81%	$362.68	+162.6%
VRTX Vertex Pharmaceuticals Inc	Strong Buy	39	79%	$438.34	-2.3%
REGN Regeneron Pharmaceuticals	Strong Buy	36	75%	$76.80	-89.6%
ALNY Alnylam Pharmaceuticals Inc	Strong Buy	36	78%	$102.31	-66.8%
INSM Insmed Inc	Strong Buy	26	92%	$143.40	+3.1%
NTRA Natera Inc	Strong Buy	27	89%	$142.91	-26.5%